Full-Time

Rare Disease Account Manager

Nephrology

Posted on 8/20/2026

Otsuka Pharmaceutical

Otsuka Pharmaceutical

1,001-5,000 employees

Global pharma maker of Abilify

Compensation Overview

$132k - $205.4k/yr

+ Incentive opportunity

Orlando, FL, USA

Hybrid

The role includes a remote-sales location and an Orlando office location; periodic customer and congress travel may be required.

Bachelor's, Master's, MBA

Category
Sales & Account Management (1)
Required Skills
Sales
Data Analysis

Get referred to Otsuka Pharmaceutical

See people who can refer or advise you

Requirements
  • A bachelor's degree is required.
  • At least 3 years of sales experience in rare disease, immunology, renal, oncology, and/or hospital account management is strongly preferred.
  • A proven track record of consistently meeting or exceeding financial or other quantitative targets and qualitative goals in a fast-paced, dynamic sales environment is required.
  • The candidate must demonstrate intellectual curiosity, business acumen, perseverance, relationship mastery, collaboration, and passion for the patient.
  • The candidate must be able to interpret, analyze, and leverage data to identify trends, gain insights, drive pull-through, and lead live customer engagements in the local business environment.
  • The candidate must demonstrate strategic thinking to create a dynamic and collaborative customer or account engagement plan.
  • The candidate must maintain ongoing awareness of trends in their area of expertise and leverage knowledge and insights to positively impact the business.
  • The candidate must collaborate respectfully with internal and external stakeholders, including payers, health systems, and matrix partners, in a complex and competitive healthcare environment.
  • The candidate must apply expert knowledge of the marketplace, applicable competitors, industry, and matrix functional activities or plans to anticipate and manage business opportunities and challenges in an ambiguous environment.
  • The candidate must demonstrate a commitment to ethical business practices, understand regulatory standards, and execute business activities in compliance with company policies and guidance.
Responsibilities
  • Report directly to the Area Business Lead, Rare Disease, and coordinate with cross-functional colleagues in Medical, Market Access, Patient Support, and Thought Leader Liaison functions.
  • Serve as the main point of contact for healthcare provider customers and accounts.
  • Develop a territory-specific business or account plan with strategies and tactics to increase disease-state awareness, implement diagnostic approaches, identify and pursue business opportunities, and meet sales goals in the rare disease space.
  • Communicate and collaborate within a cross-functional team, including other Rare Disease Account Managers, brand marketing, market access, medical affairs, and thought leader liaisons, to meet business objectives.
  • Develop in-depth knowledge of current and future competition and execute sales strategies to compete effectively and achieve patient acquisition and revenue goals.
  • Build and maintain proficiency in relevant disease states, patient and clinic experience, the market landscape, and product knowledge.
  • Use available tools, technology, and resources to analyze and identify market opportunities and trends.
  • Navigate the dynamic healthcare landscape and identify opportunities across academic institutions, integrated delivery networks, community practices, and local patient advocacy groups.
  • Execute the rare disease selling model.
  • Sponsor and display at relevant congresses and society meetings.
  • Use expertise in longer sales cycles and complex patient journeys across the product portfolio.
  • Use competitive data and business reports, including sales data and promotional budgets, to track progress and uncover opportunities.
  • Assess territory and business conditions that affect sales results and establish near-term priorities for the territory business plan.
  • Respond compliantly to competitive threats and opportunities.
  • Educate office staff on payer guidelines and reimbursement procedures to increase pull-through.
  • Use promotional materials effectively.
  • Maintain awareness of internal support-team resources available throughout the ecosystem and use them appropriately.
  • Apply market and industry knowledge to overcome objections and influence prescribing habits during the total office call.
  • Identify territory professional groups for networking and access to potential key opinion leaders.
  • Build relationships with office and practice personnel, focus on patient health in conversations, and provide accurate information and follow-through to accounts.
  • Deliver balanced office calls and sales presentations using approved marketing materials and technical references, including studies and package inserts, to help healthcare providers enhance patient outcomes.
  • Demonstrate product knowledge of the company's products and competing products.
  • Facilitate clinical dialogue that encourages customers to act on behalf of patients and engage the entire account to identify obstacles and provide appropriate solutions.
  • Develop and position Otsuka as a leader with key Nephrology stakeholders, specialty customers, and targeted large-group and community practices.
Desired Qualifications
  • An MBA or other related graduate degree is preferred.
  • Sales experience in rare disease, immunology, renal, oncology, and/or hospital account management is strongly preferred.
Otsuka Pharmaceutical

Otsuka Pharmaceutical

View

Otsuka Pharmaceutical develops and markets medicines and health products worldwide, including prescription drugs and nutraceutical beverages. Its product lineup ranges from pharmaceutical treatments such as Abilify (an antipsychotic) to consumer health drinks like Pocari Sweat, which helps replenish electrolytes. Abilify works as a psychiatric medication used to treat conditions such as schizophrenia and bipolar disorder, while Pocari Sweat is an ion-replacement beverage designed to restore minerals and fluids after activity or heat. The company differentiates itself through a long history dating back to its founding in 1921, a broad, globally scaled portfolio spanning drugs and health beverages, and a focus on health improvements across populations. Its stated goal is to create new products for better health worldwide.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Tokyo, Japan

Founded

1921

Get referred to Otsuka Pharmaceutical

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Otsuka closed Transcend in June 2026, expanding psychiatry beyond Abilify dependence.
  • DAWNZERA gained EU authorization in January 2026, opening paid sales across 27 countries.
  • Paradise uRDN and CART BP pro broaden Japan's hypertension platform and device distribution.

What critics are saying

  • SIMTRIYO waits on DEA scheduling, delaying revenue until late 2026.
  • VOYXACT's accelerated approval depends on confirmatory kidney-outcome data; failure risks withdrawal.
  • Transcend's TSND-201 PTSD program remains clinical-stage, risking a $1.225 billion write-down.

What makes Otsuka Pharmaceutical unique

  • Otsuka pairs CNS, nephrology, and device assets across Japan, US, and Europe.
  • SIMTRIYO gives Otsuka a first-in-class ADHD stimulant franchise after July 2026 FDA approval.
  • DAWNZERA and VOYXACT anchor rare-disease pipelines with global reimbursement and accelerated paths.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Company Match

Tuition Reimbursement

Student Loan Assistance

Paid Holidays

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Associated Press
Jul 25th, 2026
FDA approves Otsuka's Simtriyo, first-in-class ADHD treatment for adults and children 6+

Otsuka Pharmaceutical has received FDA approval for SIMTRIYO (centanafadine), the first norepinephrine, dopamine, serotonin reuptake inhibitor for treating ADHD in adults and children aged six years and older weighing at least 20kg. The once-daily extended-release capsule will be available later this year following DEA scheduling. The approval is based on four Phase 3 clinical trials showing statistically significant improvements in ADHD symptoms compared to placebo, with benefits observed as early as week one. Common side effects include decreased appetite, nausea, rash, and headache. ADHD affects approximately 7 million children and 15.5 million adults in the US. The drug carries boxed warnings for suicidal ideation in pediatric patients and potential for abuse and addiction.

SonoThera
Jun 10th, 2026
SonoThera Closes Oversubscribed $125 Million Series B Financing to Advance Clinical Development of Ultrasound-Mediated Nonviral Genetic Medicines - SonoThera

SAN FRANCISCO–SonoThera, a biotechnology company developing next-generation genetic medicines to address the root causes of disease, today announced the closing of an oversubscribed $125 million Series B financing round to advance its lead programs in Duchenne muscular dystrophy (DMD) and autosomal dominant polycystic kidney disease (ADPKD) into the clinic and expand its pipeline of targeted, redosable genetic medicines.

Dealroom.co
Mar 27th, 2026
Transcend Therapeutics company information, funding & investors

Transcend Therapeutics, developing the next generation of psychoactive compounds for neuropsychiatry focused on patient access. Here you'll find information about their funding, investors and team.

Fierce Biotech
Mar 27th, 2026
Otsuka buys Transcend Therapeutics for $700M upfront in psychiatric drugs deal

Otsuka Pharmaceutical has acquired Transcend Therapeutics for $700 million upfront through its subsidiary Otsuka America, with potential milestone payments of up to $525 million. The deal gives Otsuka access to Transcend's MDMA analogue for psychiatric conditions currently in development.

Associated Press
Mar 25th, 2026
Otsuka's Voyxact shows 82.5% hematuria improvement in IgA nephropathy trial at 48 weeks

Otsuka presented new Phase 3 VISIONARY trial data for VOYXACT (sibeprenlimab-szsi) in IgA nephropathy patients at the 2026 ISN World Congress of Nephrology. The analyses showed 82.5% of patients receiving sibeprenlimab achieved negative microscopic hematuria at week 48, compared with 52.6% on placebo. Median time to achieve hematuria negativity was nine weeks versus 24 weeks for placebo. VOYXACT, approved under accelerated approval in the US, is a monoclonal antibody that inhibits APRIL, a key driver in IgAN pathogenesis. Previously reported data showed the drug met its primary endpoint with a 51.2% placebo-adjusted reduction in proteinuria at nine months. The trial continues evaluating sibeprenlimab's effect on preserving kidney function over 24 months.